Imunon Inc (IMNN) Q3 2024 Earnings Call Highlights: Promising Clinical Advances Amid Financial ... [Yahoo! Finance]
Imunon, Inc. (IMNN)
Company Research
Source: Yahoo! Finance
General and Administrative Expenses: $1.7 million for Q3 2024, down from $1.9 million in Q3 2023. Net Loss: $4.9 million or $0.34 per share for Q3 2024, compared to $3.5 million or $0.37 per share for Q3 2023. Research and Development Expenses (First Nine Months): $9.4 million for the first nine months of 2024, compared to $7.7 million for the same period in 2023. General and Administrative Expenses (First Nine Months): $5.6 million for the first nine months of 2024, compared to $7.3 million for the same period in 2023. Net Loss (First Nine Months): $14.6 million or $1.39 per share for the first nine months of 2024, compared to $14.6 million or $1.64 per share for the same period in 2023. Warning! GuruFocus has detected 2 Warning Signs with IMNN. Release Date: November 07, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Imunon Inc ( NASDAQ:IMNN ) announced groundbreaking results from their phase two Ovation stud
Show less
Read more
Impact Snapshot
Event Time:
IMNN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNN alerts
High impacting Imunon, Inc. news events
Weekly update
A roundup of the hottest topics
IMNN
News
- Imunon, Inc. (NASDAQ: IMNN) had its price target lowered by analysts at HC Wainwright from $14.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
- IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual MeetingGlobeNewswire
- IMUNON Reports Third Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire
- IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024GlobeNewswire
- IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual MeetingGlobeNewswire
IMNN
Sec Filings
- 11/7/24 - Form 8-K
- 11/7/24 - Form 10-Q
- 10/31/24 - Form 4/A
- IMNN's page on the SEC website